Krystal Biotech, Inc. (KRYS) compared with its closest peers (EXEL, HALO, APGE, KYMR, IMVT): P/E 40.5 vs industry 17.2. Peer set by Business model: Biotech (Clinical / Commercial-Stage); 10 closest by market cap; US-domiciled. First-party data.
| Company | Market Cap | P/E |
|---|---|---|
| Exelixis, Inc. (EXEL) | $13.30B | 15.5 |
| Halozyme Therapeutics, Inc. (HALO) | $12.05B | 29.1 |
| Apogee Therapeutics, Inc. (APGE) | $10.15B | -17.9 |
| Kymera Therapeutics, Inc. (KYMR) | $10.10B | -21.1 |
| Immunovant, Inc. (IMVT) | $9.16B | -9.0 |
| Vaxcyte, Inc. (PCVX) | $8.86B | -8.2 |
| Twist Bioscience Corporation (TWST) | $8.49B | -21.6 |
| ImmunityBio, Inc. (IBRX) | $8.22B | -5.2 |
| CG Oncology, Inc. Common stock (CGON) | $6.88B | -20.0 |
| Scholar Rock Holding Corporation (SRRK) | $6.61B | -13.4 |
| Stock P/E | 40.5 |
| Sector P/E (Healthcare) | 21.6 |
| Industry P/E (Pharmaceutical Products) | 17.2 |
| vs Sector | 87.7% |
| vs Industry | 136.0% |
KRYS overview · KRYS earnings · KRYS financials · KRYS KPIs · KRYS investor relations · KRYS ownership · KRYS filings
Data sourced from U.S. SEC EDGAR filings and market data. Not personalized investment advice.